Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Core Insights - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [2] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York City, including a fireside chat on December 2 [1] Company Overview - Viking Therapeutics specializes in first-in-class or best-in-class therapies for metabolic and endocrine disorders, with two programs currently in clinical trials [2] - The company's lead program, VK2735, is a dual agonist targeting GLP-1 and GIP receptors, showing positive safety and clinical benefit in Phase 1 and Phase 2 trials [2] - VK2809, another key program, is an orally available small molecule for treating lipid and metabolic disorders, achieving primary and secondary endpoints in a Phase 2b study for NASH and fibrosis [2] - The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD), which demonstrated safety and significant reductions in VLCFAs in a Phase 1b trial [2]